PDCD1 and non-small cell lung carcinoma: Nivolumab is a fully human PD-1 antibody that disrupts PD-1-mediated signalling and has been approved for the treatment of patients with metastatic NSCLC and disease progression on or after platinum-based chemotherapy (8).